Devicare has signed a participative loan worth 2 million Euros from the Innova Global line by Avançsa, assigned to the Business and Expertise Department, with the option to convert the investment into Series A stock in the mid-term.

With this new economic injection, Devicare will continue the strategic development and validation plan of new medical solutions under the Remote Patient Monitoring concept, which simply and economically places patients at the centre of their own healthcare management, known as patient empowerment, as well as the corresponding clinical studies and trials for the expansion throughout the European and North American markets.

Francisco Cabezas, the company’s financial director, explains that "we have left the start-up phase behind. We’re now completely in the validation phase with a business model that perfectly fits Avançsa’s strategic objectives: an entrepreneurial project with an extremely innovative component and an excellent potential for international expansion, impact in the territory and feasibility."

Sensor technology for multiple medical fields

Devicare is developing a patented technology using sensors to measure biometrics in breath and body fluids such as blood, sweat, saliva and urine which can be exported for the prevention and treatment of different diseases. At present the company’s experience has focused on recurring urological diseases (Lit-Control®) and patients using anticoagulants (Tao-Control®), but the company is now collaborating with renowned centres and hospitals in Catalonia to resolve uncovered medical needs. .....

About Devicare

Devicare (www.devicare.com/en) is a company specialized in the development of innovative solutions and medical devices for the home care of chronic patients. These www.devicare.com solutions are developed under the concept of Remote Patient Monitoring (RPM) in order to enable the patient to actively participate in the monitoring of their disease. Currently, the company offers two product lines: Lit-Control® (www.lit-control.com) for the prevention and self-management of recurrent urinary diseases and Tao-Control® (www.taocontrol. com) for self-management of patients taking anticoagulants (medicines such as Sintrom® or Aldocumar®). Devicare’s headquarters is located at the UAB Research Park, in Cerdanyola del Vallès, near Barcelona (Spain).

Fuente: Devicare

Subscribe to Directory
Write an Article

Highlight

Axon moves into Cloud Technology

by Axon Partners Group

cloud technology axon

Palex, backed by Apax and Fremman, and D...

by Fremman Capital

Palex Medical has announced the execution of a put option agreement fo...

Photos Stream